- Data are a stark reminder that ET-related healthcare system costs are under-appreciated and underscore the potential of Cala Trio to address the needs of patients and payers - BURLINGAME, ...

Cala Health has finalised the initial closing of an oversubscribed growth round of $50m to support the expansion of patient access to its neurostimulation therapy. Nexus NeuroTech Ventures and Vertex ...

New analysis finds patients with Essential Tremor (ET) had a significantly higher number of comorbidities, including anxiety and depression, and higher healthcare costs compared to non-ET patients – ...

The retrospective post-market surveillance study, published in Tremor and Other Hyperkinetic Movements, found that long-term usage of Cala TAPS therapy resulted in tremor reduction and was preferred ...

Cala Health recently published a post-market surveillance study that demonstrates the long-term efficacy of its wrist-based wearable for people with essential tremor, finding that the device reduced ...

While many wearable devices currently available to people with Parkinson’s disease focus mainly on tracking the condition, the latest iteration of Cala Health’s externally worn technology is aiming to ...

SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- Cala, the bioelectronic medicine leader, today announced the results from multiple clinical studies, further strengthening evidence supporting positive ...

SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round and was recognized on Fast Company's annual top ...